Efimosfermin

Phase 2Protein / enzyme

BBoston Pharmaceuticals

Efimosfermin is one of 73 small molecule programs targeting Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Non-Alcoholic Steatohepatitis (NASH)Completed

Metabolic Dysfunction-Associated SteatohepatitisRecruiting

CirrhosisActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Non-Alcoholic Steatohepatitis (NASH)Phase 2

Completed

Metabolic Dysfunction-Associated SteatohepatitisPhase 2

Recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

9 2

Efimosfermin

BBoston Pharmaceuticals

Phase 2

2 3

Crestor

AstraZeneca

Preclinical

2 4

Farxiga

AstraZeneca

Preclinical

1 5

Thalomid

Bristol-Myers Squibb

Preclinical

1 6

Cipro

Bayer

Preclinical

1 7

Dobutrex

Eli Lilly

Preclinical

1 8

Azulfidine

Pfizer

Preclinical

1 9

HEPCLUDEX

Gilead

Preclinical

1 10

Coreg

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatohepatitis

NCT06920043

Clinical

Trials by Indication[1]

Non-alcoholic Steatohepatitis (NASH)1 trial

A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension

Completed·BBoston Pharmaceuticals·Phase 2·NCT04880031·231 enrolled

Metabolic Dysfunction-associated Steatohepatitis1 trial

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting·BBoston Pharmaceuticals·Phase 2·NCT06920043·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Efimosfermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Efimosfermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Efimosfermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: BBoston Pharmaceuticals

Efimosfermin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Non-alcoholic Steatohepatitis (NASH)1 trial

Metabolic Dysfunction-associated Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News